MiRNA-15a/16: As tumor suppressors and more

Future Oncology

Volumn 11, Issue 16, 2015, Pages 2351-2363

  Huang, Enyu ^a   Liu, Ronghua ^a   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

angiogenesis; cancer hallmarks; cancer therapy; immune regulator; miRNA

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MICRORNA; MICRORNA 15; MICRORNA 15A; MICRORNA 15B; MICRORNA 16; MICRORNA 16 1; MICRORNA 16 2; MIRAVIRSEN; PEMETREXED; RETINOIC ACID; SMALL INTERFERING RNA; TAMOXIFEN; UNCLASSIFIED DRUG; VINCRISTINE; VORINOSTAT; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; GENE CLUSTER; GENE FUNCTION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; TUMOR SUPPRESSOR GENE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOMODULATION; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY);

GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOMODULATION; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84939188329     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.101     Document Type: Review

References (67)

1. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and mir16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99(24), 15524-15529 (2002).
2. Yang TQ, Lu XJ, Wu TF et al. MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-kappab1/mmp9 signaling pathway. Cancer Sci. 105 (3), 265-271 (2014).
3. Qian J, Jiang B, Li M, Chen J, Fang M. Prognostic signifcance of microRNA-16 expression in human colorectal cancer. World J. Surg. 37(12), 2944-2949 (2013).
4. Jiang QQ, Liu B, Yuan T. MicroRNA-16 inhibits bladder cancer proliferation by targeting cyclin d1. Asian Pac. J. Cancer Prev. 14(7), 4127-4130 (2013).
5. Agra Andrieu N, Motino O, Mayoral R et al. Cyclooxygenase-2 is a target of miRNA-16 in human hepatoma cells. PLoS ONE 7(11), e50935 (2012).
6. Bonci D, Coppola V, Musumeci M et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14(11), 1271-1277 (2008).
7. Dejean E, Renalier MH, Foisseau M et al. Hypoxia-microRNA-16 down regulation induces vegf expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas. Leukemia 25(12), 1882-1890 (2011).
8. Scaglione BJ, Salerno E, Balan M et al. Murine models of chronic lymphocytic leukaemia: role of miRNA-16 in the new zealand black mouse model. Br. J. Haematol. 139(5), 645-657 (2007).
9. Raveche ES, Salerno E, Scaglione BJ et al. Abnormal miRNA-16 locus with synteny to human 13q14 linked to cll in nzb mice. Blood 109(12), 5079-5086 (2007).
10. Liu J, Chen G, Feng L et al. Loss of p53 and altered miR15-a/16-1 short right arrow MCL-1 pathway in cll: Insights from TCL1-TG:P53 (-/-) mouse model and primary human leukemia cells. Leukemia 28(1), 118-128 (2014).
11. Fabbri M, Bottoni A, Shimizu M et al. Association of a miRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 305(1), 59-67 (2011).
12. Teshima K, Nara M, Watanabe A et al. Dysregulation of BMI1 and miRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma. Oncogene 33(17), 2191-2203 (2014).
13. Zhang X, Chen X, Lin J et a l. Myc represses miR-15a/miR-16-1 expression through recruitment of hdac3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 31(24), 3002-3008 (2012).
14. Gao SM, Xing CY, Chen CQ, Lin SS, Dong PH, Yu FJ. MiR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating wt1 protein level. J. Exp. Clin. Cancer Res. 30, 110 (2011).
15. Gao SM, Yang J, Chen C et al. MiR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid. Leuk. Lymphoma 52(12), 2365-2371 (2011).
16. Chamorro-Jorganes A, Araldi E, Penalva LO, Sandhu D, Fernandez-Hernando C, Suarez Y Microrna-16 and miRNA-424 regulate cell-autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fbroblast growth factor receptor-1. Arterioscler. Thromb. Vasc. Biol. 31(11), 2595-2606 (2011).
17. Spinetti G, Fortunato O, Caporali A et al. MicroRNA-15a and miRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ. Res. 112(2), 335-346 (2013).
18. Jang JY, Lee JK, Jeon YK, Kim CW. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infltration and m2 polarization. BMC Cancer 13, 421 (2013).
19. Marcais A, Blevins R, Graumann J et al. Microrna-mediated regulation of mtor complex components facilitates discrimination between activation and anergy in CD4 T cells. J. Exp. Med. 211(11), 2281-2295 (2014).
20. Rouse M, Rao R, Nagarkatti M, Nagarkatti PS. 3, 3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through miRNA signaling pathways. J. Pharmacol. Exp. Ther. 350(2), 341-352 (2014).
21. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. Micrornas modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase ikkalpha during macrophage differentiation. Nat. Immunol. 11(9), 799-805 (2010).
22. Zhou R, Li X, Hu G, Gong AY, Drescher KM, Chen XM. MiR-16 targets transcriptional corepressor smrt and modulates NF-kappaB-regulated transactivation of interleukin-8 gene. PLoS ONE 7(1), e30772 (2012).
23. Min S, Liang X, Zhang M et al. Multiple tumor-associated miRNAs modulate the survival and longevity of dendritic cells by targeting ywhaz and bcl2 signaling pathways. J. Immunol. 190(5), 2437-2446 (2013).
24. Lerner M, Harada M, Loven J et al. Dleu2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory miRNAs miR-15a and miR-16-1. Exp. Cell Res. 315(17), 2941-2952 (2009).
25. Ma Q, Wang X, Li Z et al. MicroRNA-16 represses colorectal cancer cell growth in vitro by regulating the p53/survivin signaling pat hway. Oncol. Rep. 29 (4), 1652-1658 (2013).
26. Cui X, Witalison EE, Chumanevich AP et al. The induction of miRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS ONE 8(1), e53791 (2013).
27. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H. P53-induced miR-15a/16-1 and ap4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res. 74(2), 532-542 (2014).
28. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA. The mrna stability factor hur inhibits miRNA-16 targeting of COX-2. Mol. Cancer Res. 10(1), 167-180 (2012).
29. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. The mrna binding proteins hur and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136(5), 1669-1679 (2009).
30. Takeshita F, Patrawala L, Osaki M et al. Systemic delivery of synthetic miRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol. Ther. 18(1), 181-187 (2010).
31. Zhu C, Ren C, Han J et al. A fve-miRNA panel in plasma was identifed as potential biomarker for early detection of gastric cancer. Br. J. Cancer 110(9), 2291-2299 (2014).
32. Wang H, Wang L, Wu Z et al. Three dysregulated miRNAs in serum as novel biomarkers for gastric cancer screening. Med. Oncol. 31(12), 298 (2014).
33. Liu J, Gao J, Du Y et al. Combination of plasma miRNAs with serum CA19-9 for early detection of pancreatic cancer. Int. J. Cancer 131(3), 683-691 (2012).
34. Tian Y, Xue Y, Ruan G et al. Interaction of serum miRNAs and serum folate with the susceptibility to pancreatic cancer. 44(1), 23-30 (2015).
35. Ell B, Mercatali L, Ibrahim T et al. Tumor-induced osteoclast mirna changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24(4), 542-556 (2013).
36. Chen D, Li Y, Yu Z et al. Upregulated miRNA-16 as an oncogene in renal cell carcinoma. Mol. Med. Rep. 12(1), 1399-404 (2015).
37. Nam EJ, Yoon H, Kim SW et al. Microrna expression profles in serous ovarian carcinoma. Clin. Cancer Res. 14 (9), 2690-2695 (2008).
38. Miles GD, Seiler M, Rodriguez L, Rajagopal G, Bhanot G. Identifying miRNA/mRNA dysregulations in ovarian cancer. BMC Res. Notes 5, 164 (2012).
39. Gattolliat CH, Uguen A, Pesson M et al. Microrna and targeted mrna expression profling analysis in human colorectal adenomas and adenocarcinomas. Eur. J. Cancer 51(3), 409-420 (2015).
40. Maclellan SA, Lawson J, Baik J, Guillaud M, Poh CF, Garnis C. Differential expression of mirnas in the serum of patients with high-risk oral lesions. Cancer Med. 1(2), 268-274 (2012).
41. Weber AJ, Soong G, Bryan R, Saba S, Prince A. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR traffcking and Cl-channel function. Am. J. Physiol. Lung Cell. Mol. Physiol. 281(1), L71-L78 (2001).
42. McDermott AM, Kerin MJ, Miller N. Identifcation and validation of mirnas as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. PLoS ONE 8(12), e83718 (2013).
43. Davoren PA, Mcneill RE, Lowery AJ, Kerin MJ, Miller N. Identifcation of suitable endogenous control genes for miRNA gene expression analysis in human breast cancer. BMC Mol. Biol. 9, 76 (2008).
44. Xiang M, Zeng Y, Yang R et al. U6 is not a suitable endogenous control for the quantifcation of circulating miRNAs. Biochem. Biophys. Res. Commun. 454(1), 210-214 (2014).
45. Peng WZ, Ma R, Wang F, Yu J, Liu ZB. Role of miR-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. Int. J. Mol. Sci. 15(3), 4031-4048 (2014).
46. Szabo DR, Luconi M, Szabo PM et al. Analysis of circulating miRNAs in adrenocortical tumors. Lab. Invest. 94(3), 331-339 (2014).
47. Chyrchel B, Toton-Zuranska J, Kruszelnicka O et al. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets doi :10.3109/09537104.2014.974527 (2014) (Epub ahead of print).
48. Leite KR, Tomiyama A, Reis ST et al. MicroRNA expression profles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol. Oncol. 31(6), 796-801 (2013).
49. Schaefer A, Jung M, Mollenkopf HJ et al. Diagnostic and prognostic implications of miRNA profling in prostate carcinoma. Int. J. Cancer 126(5), 1166-1176 (2010).
50. Cascione L, Gasparini P, Lovat F et al. Integrated miRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS ONE 8(2), e55910 (2013).
51. Zuo Z, Calin GA, De Paula HM et al. Circulating miRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 118(2), 413-415 (2011).
52. Xi Y, Li J, Zan L, Wang J, Wang G, Ning Y. Micro-RNA-16 expression in paraffn-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia. Hum. Pathol. 44 (6), 1011-1016 (2013).
53. Liu X, Luo HN, Tian WD et al. Diagnostic and prognostic value of plasma miRNA deregulation in nasopharyngeal carcinoma. Cancer Biol. Ther. 14(12), 1133-1142 (2013).
54. Gao X, Zhang R, Qu X et al. M i R-15 a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk. Res. 36 (12), 1505-1509 (2012).
55. Poell JB, Van Haastert RJ, De Gunst T et al. A functional screen identifes specifc miRNAs capable of inhibiting human melanoma cell viability. PLoS ONE 7(8), e43569 (2012).
56. Navarro A, Diaz T, Gallardo E et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. J. Surg. Oncol. 103 (5), 411-415 (2011).
57. Bandi N, Zbinden S, Gugger M et al. MiR-15a and miR-16 are implicated in cell cycle regulation in a rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 69 (13), 5553-5559 (2009).
58. Wang Y, Gu J, Roth JA et al. Pathway-based serum miRNA profling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73(15), 4801-4809 (2013).
59. Pouliot LM, Chen YC, Bai J et al. Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res. 72(22), 5945-5955 (2012).
60. Reid G, Pel ME, Kirschner MB et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann. Oncol. 24(12), 3128-3135 (2013).
61. Xia L, Zhang D, Du R et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 123(2), 372-379 (2008).
62. Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic her2{delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31(12), 2049-2057 (2010).
63. Kasar S, Underbayev C, Yuan Y et al. Therapeutic implications of activation of the host gene (DLEU2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia. Oncogene 33(25), 3307-3315 (2014).
64. Bader AG. MiR-34-a miRNA replacement therapy is headed to the clinic. Front. Genet. 3, 120 (2012).
65. Misso G, Di Martino MT, De Rosa G et al. MiR-34: a new weapon against cancer? Mol. Ther. Nucleic Acids 3, e194 (2014).
66. Mirna Therapeutics, Inc. A multicenter Phase I study of MRX34, microRNA miR-RX34 liposomal injection. 2014. https://clinicaltrials.gov
67. Santaris Pharma A/S. Santaris Pharma A/S presents fnal Phase 2a study results for miravirsen showing dose-dependent, prolonged antiviral activity in hepatitis C patients. (2012). www.prnewswire.com